India Health Expo 2026 Moves From Generics to Biosimilars and AI

For hospital systems, payers, and digital health vendors that rely on India's low-cost generic supply, the message from New Delhi is that the next wave of Indian pharma growth will come from higher-value biologics and AI-driven processes, not just volume generics. That shift has direct implications for drug costs, biosimilar competition, and the resilience of global medicine supply chains.

India’s pharmaceutical policy debate entered a new, explicit phase on September 6, 2026, when Union Commerce Minister Piyush Goyal inaugurated the Bharat Health Global Expo 2026 at Bharat Mandapam in New Delhi and used the platform to outline an innovation-led path for a sector that has built its global reputation on low-cost generics. The remarks, reported by ANI and carried by multiple outlets, were not merely ceremonial. They signaled that the Indian government believes the industry must now move beyond manufacturing inexpensive copycat drugs and compete in complex, patent-protected, higher-value categories such as biosimilars and biotechnology.

“

Commerce and Industry Minister of State Jitin Prasada added a technological dimension to the same argument.

Goyal was direct about the legacy and its limits. He acknowledged that India has become a generics success story through the active work of the pharma industry, but he warned that the country cannot rest its case with generics. Instead, he called for promoting more R&D, patenting Indian products, and putting pharma at the forefront of research and innovation. He named biosimilars and biotech as the next frontier, a statement that places biologics at the center of India’s next industrial policy push. This is significant because biosimilars require far more complex manufacturing, regulatory science, and clinical capabilities than small-molecule generics, and the global biosimilar market is dominated by a small group of companies — a gap India clearly wants to close.

The regulatory message was equally pointed. Goyal said India needs a regulatory environment where R&D and innovation become attractive, with greater openness to investments in clinical trials, patenting, research, and new product development. He called for closer regulatory convergence with developed markets and a policy approach that listens to investors and responds to what global markets require. These remarks suggest that Indian officials understand that becoming a biotech and biosimilar leader is not just a matter of industrial ambition; it requires changes to how clinical research is approved, how intellectual property is protected, and how quality standards are monitored. Without those changes, global innovators may continue to view India primarily as a manufacturing destination rather than a co-development partner.

Commerce and Industry Minister of State Jitin Prasada added a technological dimension to the same argument. He said India’s next phase will move from affordable medicines toward pharmaceutical innovation, and that technology adoption will be critical. In particular, he said artificial intelligence will have to be adopted across the pharmaceutical value chain if Indian companies are to remain competitive and move to the next level. That is an important acknowledgment that AI is not just a back-office efficiency tool but a competitive necessity in drug discovery, clinical development, manufacturing quality, regulatory documentation, and supply-chain management. For a country with a large IT talent base, this could become a distinctive advantage if the pharma and tech sectors align.

Goyal also reframed resilience in a way that avoids protectionism. He said the world is looking for resilience, but resilience does not mean being inward-looking. Instead, it means ensuring supply chains are diversified across geographies and companies while identifying areas where India has the potential to build indigenous capabilities. This is a balancing act: India wants to attract global investment and participate in global supply chains, but it also wants to reduce dependence on imports in critical areas. For global buyers and health systems that rely on Indian drugs, the statement is a reassuring signal that India is not pursuing autarky, but it also indicates that the country intends to move into more sophisticated segments of the value chain.